Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06351527 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
A Phase 1 study of Mature B-cell Malignancies, sponsored by InnoCare Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 8
- Study locations
NCT06351527: Recruiting Phase 1 study of Mature B-cell Malignancies, sponsored by InnoCare Pharma.
NCT06351527 is a Phase 1 study of Mature B-cell Malignancies that is actively recruiting participants, run by InnoCare Pharma. The registered enrollment target is 78 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06351527, a Phase 1 study of Mature B-cell Malignancies, is actively recruiting participants, sponsored by InnoCare Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 8
- Study locations
Study Summary
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Primary Outcome
Dose-limiting toxicity (DLT) rate at each dose level DLT will be assessed via CTCAE version 5.0 or iwCLL 2018.
Conditions Studied
Interventions
- DRUG ICP-248
- DRUG Obinutuzumab (G)
- DRUG Rituximab (R)
Study Locations (8)
Other
- Pan American Center for Oncology Trials - San Juan
- CNE CCOHTPC of Cherkasy Regional Council - Cherkasy
- CNE"City Clin Hosp#4"of Dnipro City Council - Dnipro
- Medical Center of Limited Liability Company Arensia Exploratory Medicine - Kyiv
- Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC - Kyiv
- SI Institute of Blood Pathology and Transfusion Medicine of AMSU - Lviv
Florida
- BRCR Medical Center - Plantation
New York
- Clinical Research Alliance - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 1 |
What NCT06351527 shows while recruiting
NCT06351527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Mature B-cell Malignancies appearing as the primary indexed condition, and to 3 interventions - of which ICP-248 is the first listed.
NCT06351527 lists 8 locations in 3 states (Other, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT06351527 about?
NCT06351527 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies". Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
What is the current status of trial NCT06351527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-04-23. Estimated completion is 2027-10-25.
What conditions does trial NCT06351527 study?
This clinical trial studies the following conditions: Mature B-cell Malignancies.
What interventions are being tested in trial NCT06351527?
The interventions under investigation include: ICP-248 (DRUG), Obinutuzumab (G) (DRUG), Rituximab (R) (DRUG).
Who is sponsoring clinical trial NCT06351527?
This trial is sponsored by InnoCare Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06351527 being conducted?
This trial has 8 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mature B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06351527's enrollment target sits among peer trials
78 698th of 2000 higher than 1,298 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI